CMRX - Koefisien bali modal nimbang wutah Chimerix, Inc.

Chimerix, Inc. (CMRX) is overcoming stringent FDA oversight and high R&D costs by leveraging its oncology patents. Risks are being mitigated through government contracts and the development of antiviral agents. The PEG ratio reflects the valuation dynamics relative to earnings, where the current metric is 0.00. Stability is ensured by a substantial cash reserve to fund prolonged clinical trials.

CMRX Rasio rega marang bathi tumrap wutah Chimerix Inc (04.07.2022 - 26.04.2025)

Rincian metrik lan analitis perusahaan Chimerix, Inc. (CMRX)

- rega saiki lan proyeksi nilai saham:

Bagan rega Chimerix Inc.|CMRX - Target konsensus

- statistik kapitalisasi pasar:

Nilai pasar Chimerix, Inc|CMRX - Nilai Total Perusahaan

- indikator kapitalisasi buku:

Nilai Aset Bersih saben Saham Chimerix|CMRX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku chimerix.com|CMRX - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi lan kelipatan valuasi:

CMRX - Penghasilan resik|Bathi resik sing dikarepake Chimerix, Inc.|CMRX - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Chimerix Inc|CMRX - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Chimerix, Inc|CMRX - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Chimerix|CMRX - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan chimerix.com|CMRX - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Chimerix, Inc.

Analisis fundamental perusahaan:Chimerix Inc. CMRX

Demand for Chimerix, Inc. (CMRX) smallpox treatments amid geopolitical tensions is facing logistical barriers, making the PEG ratio dynamics a key analytical tool. This metric compares the P/E ratio with earnings growth rates, identifying an undervalued asset when the value is below one; thus, an investor can filter out market noise and identify the potential for a sharp surge in share prices.

Pesaing Chimerix, Inc.

Rasio rega marang bathi tumrap wutah INCY (Incyte Corp)|HUTCHMED Ltd - Pangali rega marang bathi tumrap wutah|Koefisien bali modal nimbang wutah NUVB|DAWN - Rasio rega marang bathi tumrap wutah|Rega marang bathi kanthi panyesuaian wutah monopartx.com|Inhibrx Biosciences, Inc. (INBX) - Rasio rega marang bathi tumrap wutah|Rasio P/E diaturake wutah IMAB|FENC (Fennec Pharmaceuticals Inc) - Pangali PEG|Pangali rega marang bathi tumrap wutah Heron Therapeutics Inc (HRTX)|Rasio rega marang bathi tumrap wutah Nuvectis Pharma, Inc. (NVCT)|CHRS - Rega marang bathi kanthi panyesuaian wutah|Rasio rega marang bathi tumrap wutah Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Rasio rega marang bathi tumrap wutah|BYSI - Rasio rega marang bathi tumrap wutah|Rega marang bathi kanthi panyesuaian wutah BioAtla, Inc.|LIXT: Pangali PEG|Rasio rega marang wutah bathi resik Citius Pharmaceuticals, Inc. CTXR|Pangali rega marang bathi tumrap wutah CLRB|Rega marang bathi kanthi panyesuaian wutah BioLineRx Ltd BLRX|Pangali rega marang bathi tumrap wutah CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Koefisien bali modal nimbang wutah|Kazia Therapeutics Limited - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang wutah bathi SLXN (Silexion Therapeutics Corp.)|NuCana Corp - Pangali PEG|Koefisien bali modal nimbang wutah CYCC (Cyclacel Pharmaceuticals, Inc.)|GTHX: Pangali PEG|Rega marang bathi kanthi panyesuaian wutah Kronos Bio Corporation (KRON)|Rasio rega marang bathi tumrap wutah Kintara Therapeutics|ONCT: Koefisien bali modal nimbang wutah|Pangali PEG PRTG